Merck Shares Up 14.8% as RBC Labels It Defensive AI Pharma Winner
Merck shares gained 14.8% over the past month versus a 1.4% industry rise as RBC identifies it among defensive AI pharma winners alongside Lilly and AbbVie. Zacks downgraded Merck to a #4 (sell) after analysts cut its current-quarter EPS estimate by 228% to a $0.41 loss.
1. Share Performance Over Past Month
Merck shares gained 14.8% over the last month, outperforming the Zacks Large Cap Pharmaceuticals industry’s 1.4% gain and signaling strong investor confidence in its pipeline.
2. RBC Identifies Merck as Defensive AI Pharma Winner
RBC highlighted Merck among large-cap pharma names deemed defensive AI winners, pointing to its advanced AI-driven research initiatives and robust cash flow generation alongside peers Lilly and AbbVie.
3. Zacks Earnings Estimate Revisions and Downgrade
Analysts slashed Merck’s current-quarter EPS estimate by 228% to a $0.41 loss over the past 30 days, triggering a Zacks Rank #4 (sell) that suggests potential underperformance in the near term.
4. Revenue Growth and Valuation Outlook
The Zacks Consensus projects $16.01 billion in Q1 sales (+3.1% y/y), $66.68 billion for fiscal year (+2.6%) and $70.7 billion next year (+6%), while valuation metrics earn a C grade relative to peers.